Welcome to our dedicated page for EXICURE SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure, Inc. reported a smaller net loss for 2025 but highlighted serious liquidity challenges. Net loss narrowed to $4.9 million from $9.7 million in 2024, helped by a $6.0 million gain from early termination of its Chicago office lease.
Cash and cash equivalents fell sharply to $3.7 million as of December 31, 2025, from $12.5 million a year earlier. Management states this cash is not sufficient to fund operations, and that substantial additional financing is needed in the short term to pay expenses and continue exploring strategic alternatives.
Following the acquisition of GPCR Therapeutics USA Inc., research and development expenses rose to $3.3 million from zero, while general and administrative expense increased to $6.8 million from $5.4 million, mainly due to acquisition and integration costs. Revenue was $0 in 2025 versus $0.5 million in 2024.
Exicure, Inc. Chief Accounting Officer Josh Miller reported a small tax-related share disposition. On February 16, 2026, 8 shares of common stock at $4.08 per share were withheld by Exicure to cover his tax obligation upon vesting of restricted stock units. After this withholding, Miller directly holds 301 shares of Exicure common stock. This was a tax-withholding disposition under code F, not an open-market sale.
Exicure, Inc. reported a leadership change, appointing Jung Soo Kim as Chief Executive Officer and President and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. These appointments follow the resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik, effective February 9, 2026.
The company highlights Mr. Kim’s more than 20 years of experience in corporate strategy, capital markets and restructuring, and Mr. Lee’s background in governance restructuring, financial planning and regulatory compliance, including their current roles at AGEDB Technology. Exicure’s board also approved that CEO and Interim CFO services will be provided under executive services agreements with Innocircle Advisors Inc.
Exicure, Inc. reported significant leadership and board changes. On February 6, 2026, three directors — Andy Yoo, Seung Ik Baik, and Aejin Hwang — resigned from the Board effective February 9, 2026, with the company stating there were no disagreements over operations or policies.
The Board simultaneously appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with staggered terms through the 2026, 2027, and 2028 annual meetings, and named Mr. Cheon to the audit committee. Each new director will receive a $20,000 annual retainer.
The Board also approved a one-time $20,000 cash payment to each of the two remaining directors, Dongho Lee and Sangjin Yeo, and to outgoing director Hwang. On the same date, Yoo resigned as Chief Executive Officer and President, and Baik resigned as Chief Financial Officer and Secretary, effective February 9, 2026. The Board has not yet appointed successors, and Baik received a $150,000 separation payment.
Exicure, Inc. reported achieving the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., tied to completing a Phase 2 clinical trial of its novel stem cell mobilizer (CXCR4 inhibitor Burixafor, GPC‑100). The milestone was reached when the Clinical Study Report was formally submitted to the U.S. Food and Drug Administration on January 16, 2026. Under the agreement, Exicure must pay $1,000,000 to GPCR Therapeutics within 30 days, and completion of this milestone also triggers a future sublicensing income‑sharing ratio that increases Exicure’s participation in the long‑term economics of the program.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has updated its ownership report after selling part of its stake. On January 21, 2026, Exicure HiTron completed a share transfer of 258,367 common shares at $4.50 per share, for total proceeds of $1,162,651.5. The shares were sold under share transfer agreements dated December 30, 2025 and were transferred to Jeon Sungchan for liquidity purposes.
After this transaction, Exicure HiTron reports beneficial ownership of 1,598,947 Exicure common shares, which represents about 25.1% of the company’s outstanding common stock. The ownership percentages are based on 6,373,869 shares outstanding as of November 3, 2025, as disclosed in Exicure’s Form 10-Q.
Exicure HiTron Inc., a more than 10% owner of Exicure, Inc. (XCUR), reported a sale of common stock. On 01/21/2026, the reporting person sold 258,367 shares of Exicure common stock at a price of $4.5 per share in an open-market transaction coded as "S" for sale.
After this transaction, Exicure HiTron Inc. beneficially owned 1,598,947 shares of Exicure common stock, held in direct ownership form. This filing is a routine Form 4 disclosure of insider activity and does not by itself describe any change to Exicure’s underlying business operations.
Exicure HiTron Inc. filed Amendment No. 4 to its Schedule 13D on Exicure, Inc., updating its ownership after a significant share transfer. On January 16, 2026, Exicure HiTron completed the transfer of 734,747 shares of Exicure common stock at $4.50 per share, for total proceeds of $3,306,361.5. The shares were transferred to Daolam Co., Ltd (246,913 shares), Lee So Jung (243,918 shares), and Kim Jun Sue (243,916 shares).
After these transfers, Exicure HiTron reports beneficial ownership of 1,857,314 shares of Exicure common stock, representing approximately 29.2% of the 6,373,869 shares outstanding as reported in Exicure’s Form 10-Q. The filing reflects updated ownership and transaction details but does not change Exicure HiTron’s status as a major shareholder.
Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), reported an open market sale of 734,747 shares of common stock on January 16, 2026 at a price of $4.5 per share. After this transaction, Exicure HiTron Inc. beneficially owned 1,857,314 shares of Exicure common stock, held in direct ownership form.
Exicure HiTron Inc., a major shareholder of Exicure, Inc., has amended its beneficial ownership report after selling part of its stake. On January 7, 2026, Exicure HiTron completed share transfer agreements covering 741,272 common shares at $4.50 per share, for total proceeds of $3,335,724. The shares were sold for liquidity purposes to three individuals: Im Sung Jin, Lee Aram, and Im Bumjin.
After giving effect to these transfers, Exicure HiTron reports beneficial ownership of 2,592,061 Exicure common shares, representing about 40.7% of the 6,373,869 shares outstanding as of November 3, 2025. Exicure HiTron retains sole voting and dispositive power over these remaining shares.